Sodium Monosialotetrahexosylganglioside

Objective:This study aimed to evaluate the therapeutic effect of intratympanic injection of ganglioside in patients with refractory sudden deafness. Methods:A total of 120 patients with sudden deafness, aged 18-65 years, whose onset was within 11-42 days, failed to respond to conventional treatment, and had an average hearing threshold（500-4 000 Hz）>60 dB were selected. They were prospectively and randomly divided into a control group of 61 cases and an experimental group of 59 cases. The control group was treated according to the recommended protocol of the Chinese Medical Association（postauricular injection of methylprednisolone）, while the experimental group was treated with intratympanic injection of monosialotetrahexosylganglioside sodium+postauricular injection of methylprednisolone. Both groups were simultaneously administered oral ginkgo biloba extract and citicoline tablets. Hearing was re-examined two weeks after the completion of treatment, and the therapeutic effects of the two different treatment methods were compared and analyzed. Results:The effective rate was 29.51% in the control group and 54.24% in the experimental group（P<0.01）. The average hearing threshold improved by 11.57 dB HL in the control group and 22.50 dB HL in the experimental group（P<0.05）. Conclusion:The combination of postauricular injection of methylprednisolone and intratympanic injection of ganglioside is more effective than postauricular injection of methylprednisolone alone in the treatment of refractory sudden deafness. The earlier the treatment, the better the therapeutic effect.

To determine the clinical efficacy of monosialotetrahexosylganglioside (GM1) combined with methylprednisolone in the treatment of spinal cord injury (SCI).

An observational study. Place and Duration of the Study: Department of Orthopaedics, Baoding No.1 Central Hospital, Baoding, Hebei, China, from January 2018 to June 2021.

A total of 80 patients with SCI were divided into control and observation groups according to treatment methods, the control group receiving methylprednisolone treatment and the observation group receiving methylprednisolone combined with GM1. The effective rate of treatment, time of normal muscle strength recovery, walk on the ground, and hospital stay were compared. The changes in the American Spinal Injury Association (ASIA) score, activity of daily living (ADL), serum inflammatory factors, oxidative stress factor levels, and adverse reactions were recorded.

The effective rate of clinical efficacy of the observation group was 92.50%, surpassing the control group's which was 75.00% (χ2 = 4.501, p = 0.034). The observation group had a shorter recovery time for muscle strength, walking time, and hospital stay compared to the control group (p <0.05). After treatment, the ADL scores of both groups were higher than before treatment, and the degree of increase in the observation group was higher than the control group (p <0.05). The levels of serum tumour necrosis factor-α (TNF-α) and interleukin-8 (IL-8) for all patients were significantly reduced, with the observation group showing a more significant decrease (p <0.05). There was a notable increase in glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) levels in both groups, while the levels of malondialdehyde (MDA) decreased significantly. GSH-Px, SOD, and MDA levels were significantly greater in the observation group (p <0.05).

The combination of methylprednisolone and MG1 treatment of SCI can significantly reduce the inflammatory response and improve clinical efficacy.

Spinal cord injury, Ganglioside, Methylprednisolone, Inflammatory indicators, Oxidative stress.